Personalized gene editing demands robust mechanisms for privacy, ethical governance, and verifiable data integrity. This paper proposes ViBioChain, a modular blockchain-anchored architecture integrating five components: (1) differential chain-of-custody audit combining quantum fingerprinting with post-quantum signatures for immutable genomic audit trails; (2) proof-of-bioethical-compliance employing zero-knowledge proofs and AI-based ontology evaluation for automated bioethical gating; (3) federated genomic trust mesh (FGTM) enabling privacy-preserving collaborative model training with Renyi differential privacy accounting and trust-weighted federated aggregation; (4) ethical smart orchestration network for modular smart-contract-based workflow governance; and (5) genomic impact estimator via ethical explainability graphs (GIE-EEG) for ancestry-aware, ethically constrained phenotypic forecasting. Afterexpert-driven reconciliation, the implementation was rerun using 800 simulated individuals per dataset, 120 binary loci, five institutional clients, five independent seeds (42-46), and a true trust-weighted federated logistic aggregation path for FGTM rather than the earlier centralized accuracy proxy. Across three genomic cohorts and three domain-comparable baselines, ViBioChain achieved 92.16% ethical violation interception, 100.00% audit trail accuracy, 99.47% workflow traceability, 0.9183 ethical score alignment, and the highest global model accuracy among the tested methods (74.36%). The formal Renyi differential privacy accountant remained within budget ([Formula: see text], [Formula: see text]); however, the conservative clean-versus-noisy update leakage proxy did not support the earlier lowest-empirical-leakage assertion. That claim has therefore been removed. Additional IID and non-IID experiments show that severe Dirichlet client heterogeneity ([Formula: see text]) reduced final accuracy by 1.70-4.10 percentage points relative to IID partitions. The revised results provide a more conservative and reproducible blueprint for secure, ethically governed, and explainable genomic medicine in multi-institutional settings.
Damiano Di Francesco Maesa, Francesco Donini, Paolo Mori, Laura Ricci
Non-Fungible Tokens (NFTs) are widely used nowadays for managing digital assets in many applications due to their ability to uniquely identify an asset and securely transfer and trace its ownership. Some scenarios require digital assets to be mutable, i.e., users should be allowed to update asset attributes over time, thus introducing possible security issues, since unwanted (or even malicious) updates could significantly decrease assetsâ value. While various methods for NFT mutability exist, they often lack integrated, fine-grained, and on-chain enforceable authorisation models. This paper addresses this issue by considering an NFT expansion, named Non-Fungible Mutable Token (NMT), which natively supports the update of the attributes characterising each digital asset while guaranteeing a strict and fine-grained control over such updates. In fact, the NMT approach embeds an on-chain security support based on the Attribute-Based Access Control model within the NMT architecture, aimed at regulating, through access control policies enforcement, the execution of all the update operations defined on digital assets, from new token minting to ownership transfers and attribute updates.We propose a detailed architecture for NMTs and we outline the involved smart contracts structure, including the on-chain access control system. We validate our proposal by implementing it for two common use cases, wearables and digital event tickets in the metaverse, and by conducting an experimental evaluation of the deployment and execution costs. Moreover, we simulated the usage of NMTs over a given time interval to estimate the sustainability of the proposed approach over time.
The expansion of do-it-yourself (DIY) gene editing, facilitated by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, has catalyzed a significant shift in scientific research and biotechnology innovation. This movement is propelled by a community-driven approach that challenges the traditional confines of scientific exploration, allowing amateur scientists to perform sophisticated biological experiments. While this democratization fosters inclusivity and accelerates innovation, it simultaneously introduces significant biosecurity risks. The possibility of unregulated gene editing leading to the unintentional creation of harmful organisms or the deliberate engineering of pathogens underscores the need for a new regulatory framework. This paper explores the implications of DIY biology within the context of public health, environmental safety, and biosecurity, highlighting the urgency for adaptive policies that balance scientific freedom with security. It proposes integrating community-driven regulatory practices with formal oversight mechanisms by examining biosecurity implications, ethical considerations, and the potential for misuse. Additionally, the role of decentralized autonomous organizations (DAOs) is explored as a novel approach to transforming governance within the domain of DIY gene editing, particularly in the context of CRISPR research.
Mikael Beyene, Philipp A Toussaint, Scott Thiebes, Matthias Schlesner · 6 authors
OBJECTIVE: Rising interests in distributed ledger technology (DLT) and genomics have sparked various interdisciplinary research streams with a proliferating number of scattered publications investigating the application of DLT in genomics. This review aims to uncover the current state of research on DLT in genomics, in terms of focal research themes and directions for future research. MATERIALS AND METHODS: We conducted a scoping review and thematic analysis. To identify the 60 relevant papers, we queried Scopus, Web of Science, PubMed, ACM Digital Library, IEEE Xplore, arXiv, and BiorXiv. RESULTS: Our analysis resulted in 7 focal themes on DLT in genomics discussed in literature, namely: (1) Data economy and sharing; (2) Data management; (3) Data protection; (4) Data storage; (5) Decentralized data analysis; (6) Proof of useful work; and (7) Ethical, legal, and social implications. DISCUSSION: Based on the identified themes, we present 7 future research directions: (1) Investigate opportunities for the application of DLT concepts other than Blockchain; (2) Explore people's attitudes and behaviors regarding the commodification of genetic data through DLT-based genetic data markets; (3) Examine opportunities for joint consent management via DLT; (4) Investigate and evaluate data storage models appropriate for DLT; (5) Research the regulation-compliant use of DLT in healthcare information systems; (6) Investigate alternative consensus mechanisms based on Proof of Useful Work; and (7) Explore DLT-enabled approaches for the protection of genetic data ensuring user privacy. CONCLUSION: While research on DLT in genomics is currently growing, there are many unresolved problems. This literature review outlines extant research and provides future directions for researchers and practitioners.
N. Đ. Avxentyev, Yu. V. Makarova, Đ. Đ. ĐĐ°ĐŽŃŃĐ”ĐČ
Background. New pathogenetic treatment options, such as gene therapy, are now used to treat previously uncurable diseases. However, price of such treatment is high, especially in the case of orphan diseases, where costs may many-fold exceed the prices for other types of medication. This raises a question of optimal way of financing gene therapy in Russia. Objective: to evaluate economic consequences of centralizing procurement of gene therapy in 2021â2030 in the case of the drug indicated for treatment of biallelic RPE65 mutation-associated retinal dystrophy. Material and methods. Voretigene neparvovec is a new gene therapy that is used to treat RPE65 mutation-associated Leber congenital amaurosis and isolated retinitis pigmentosa. We estimated the number of patients (children and adults) that could be treated with voretigene neparvovec in 2021â2030 in Russia using demographic forecasting method, literature and expert data. Budget costs of treatment were estimated for two scenarios: status-quo, where gene therapy is purchased by regions for higher price, and centralized scenario with federal procurements and lower price for the drug. Results. Up to 100 children and 56 adults could be treated with voretigene neparvovec in 2021â2030 in Russia. Centralizing procurements at the expense of federal budget may save up to 20.7% or 1.8 billion rub. (1.13 billion rub. for children and 0.67 billion rub. for adults), compared to regional procurements. Conclusion. Centralizing procurements of expensive drugs intended for gene therapy of orphan diseases may save budget costs of the Russian Federation, compared to status-quo decentralized purchases.
It is crucial that smart contracts are tested thoroughly due to their immutable nature. Even small bugs in smart contracts can lead to huge monetary losses. However, testing is not enough; it is also important to ensure the quality and completeness of the tests. There are already several approaches that tackle this challenge with mutation testing, but their effectiveness is questionable since they only considered small contract samples. Hence, we evaluate the quality of smart contract mutation testing at scale. We choose the most promising of the existing (smart contract specific) mutation operators, analyse their effectiveness in terms of killability and highlight severe vulnerabilities that can be injected with the mutations. Moreover, we improve the existing mutation methods by introducing a novel killing condition that is able to detect a deviation in the gas consumption, i.e., in the monetary value that is required to perform transactions. This paper has a replication package at https://github.com/pieterhartel/Mutation-at-scale
This study investigates the role and functionality of special nucleotide sequences (DNA signatures) to detect the presence of an organism and to distinguish it from all others. After highlighting vulnerabilities of the prevalent DNA signature paradigm for the identification of agricultural genetically modified (GM) organisms it will be argued that these so-called signatures really are no signatures at all - when compared to the notion of traditional (handwritten) signatures and their generalizations in the modern (digital) world. It is suggested that a recent contamination event of an unauthorized GM Bacillus subtilis strain (Paracchini et al. (2017)) in Europe could have been - or the same way could be - the consequence of exploiting gaps of prevailing DNA signatures. Moreover, a recent study (Mueller (2019)) proposes that such DNA signatures may intentionally be exploited to support the counterfeiting or even weaponization of GM organisms (GMOs). These concerns mandate a re-conceptualization of how DNA signatures need to be realized. After identifying central issues of the new vulnerabilities and overlying them with practical challenges that bio-cyber hackers would be facing, recommendations are made how DNA signatures may be enhanced. To overcome the core problem of signature transferability in bioengineered mediums, it is necessary that the identifier needs to remain secret during the entire verification process. On the other hand, however, the goal of DNA signatures is to enable public verifiability, leading to a paradoxical dilemma. It is shown that this can be addressed with ideas that underlie special cryptographic signatures, in particular those of âzero-knowledgeâ and âinvisibility.â This means more than mere signature hiding, but relies on a knowledge-based proof and differentiation of a secret (here, as assigned to specific clones) which can be realized without explicit demonstration of that secret. A reconceptualization of these principles can be used in form of a combined (digital and physical) method to establish confidentiality and prevent un-impersonation of the manufacturer. As a result, this helps mitigate the circulation of possibly hazardous GMO counterfeits and also addresses the situation whereby attackers try to blame producers for deliberately implanting illicit adulterations hidden within authorized GMOs.
Salmonella represents one of the major causes of foodborne diseases in humans, in addition to provoking important economic losses in the agri-food sector worldwide. Therefore, the surveillance and control of this human pathogenic bacterium in foodstuffs and biological fluids are necessary in order to prevent and diagnose the disease. Molecular methods based on the detection of DNA sequences specific to pathogenic species are an appealing alternative to traditional culture-based methods that require 5 to 6 days to obtain a definitive result. Among them, and because of its easy miniaturization, electrochemical genosensors are a suitable option for decentralized genetic testing [1-2]; however, they often require a set of sample pretreatment steps before genetic DNA analysis, thus making their implementation at the point of need more difficult. Herein, we report the integration of a nucleic acid-based sensor and an isothermal DNA amplification technique, helicase-dependent amplification or HDA, onto indium tin oxide (ITO) surfaces for the detection of a DNA sequence specific for the typA gene of Salmonella. DNA amplification process occurs at 65 ºC with short oligonucleotides flanking the target sequence, which act as primers. The reversed primer is covalently bound to the ITO surface through a thiol group present at its 5’ terminus, whereas forward fluorescein-tagged primer is incorporated in solution. As a result of the isothermal elongation step, fluorescein-tagged DNA duplexes are attached to the ITO surface and their enzymatic labelling is achieved via Fab fragments directed against fluorescein, conjugated with the redox enzyme alkaline phosphatase. Then, α-naphthyl phosphate is enzymatically dephosphorylated into an electroactive derivate α-naphthol whose amount, directly related to the Salmonella present in the sample, is measured by differential pulse voltammetry. This developed integrated sensing platform allows the detection of Salmonella down to 10 genomes in just over 2 hours [3], the same detection limit as that achieved by real-time PCR but without need of high-end benchtop instrumentation. Furthermore, the sensing layer built onto ITO surfaces maintains its performance even after 9 months storage, and possesses a great potential to be extended to the in-situ, fast and reliable detection of other pathogens. References: [1] D. Mabey, R.W. Peeling, A. Ustianowski and M.D. Perkins, Nat. Rev Microbiol., 2004, 2, 231-240. [2] A.S. Patterson, K. Hsieh, H.T. Soh and K.W. Plaxco, Trends Biotechnol., 2013, 31, 704-712. [3] S. Barreda-García, R. Miranda-Castro, N. de-los-Santos-Álvarez, A.J. Miranda-Ordieres, M.J. Lobo-Castañón, Chem. Comm., 2017, 53, 9721-9724. Acknowledgments: This work has been supported by the Spanish Ministerio de Economía y Competitividad (CTQ2015-63567-R), the Principado de Asturias government (FC-15-GRUPIN14-025), and co-financed by FEDER funds.
Ryan T. Gill, Andrea L. HalwegâEdwards, Aaron Clauset, Sam F. Way
An open question in biotechnology concerns the extent to which rapid advancements in DNA reading and writing technologies will shift current paradigms in the engineering of biological systems. The prevailing paradigms involve an ad hoc combination of forward engineering via serial testing of specific hypotheses and reverse engineering via random exploration of phenotypic landscapes. Combining these approaches have proven successful in many cases; however, more concerted and comprehensive approaches that leverage computational resources for experimental design visualization, modeling, and optimization at systems-level are desired. Unfortunately, we have not yet entered an era in which biological simulations can accurately predict the behavior of designed systems. Against the backdrop of increasingly affordable synthetic DNA and high-throughput testing capabilities, it is reasonable to speculate that the biological design-build-test cycle may be optimized by directly synthesizing and testing thousands of designs iteratively (Fig. 1). That is, the promise of advances in DNA synthesis and sequencing is the ability to construct and test >10,000 variants of proteins, pathways, and ultimately genomes for low cost and on laboratory timescales. This capability enables the adoption of âweakâ hypothesis approaches that allow the parallel testing of >10,000 genotype-phenotype hypotheses in machine learning driven strategies for searching combinatorial genome space. In this manner, systems biology datasets for thousands of variants can be leveraged to improve computational models, driving forward engineering via a âsynthesis aided designâ paradigm. The same strong to weak hypothesis paradigm shift began to happen in computer science almost 50 years ago. As described by Bradley Efron in a 1979 article regarding the âunthinkableâ impact that automated computation would have on the state of statistical modeling, the âunthinkableâ mentioned in the title is simply the thought that one might be willing to perform 500,000 numerical operations in the analysis of 16 data points. Or one might be willing to perform a billion operations to analyze 500 numbers. Such statements would have seemed insane 30 years ago, when a slow and noisy fifty pound desk calculator that added, subtracted, multiplied, and divided was the most sophisticated computational aid available to most scientists. Most of the statistical theory in common use was developed under the constraint of slow and expensive computation. Now computation is fast and cheap. It is not surprising that new theory is being developed, which takes advantage of the high-speed computer (Efron, 1979). This sentiment neatly describes the shift in experimental design strategies occurring today in biotechnology as we move from slow and expensive DNA synthesis to fast and cheap genome engineering. The first wave of reports demonstrating data-driven experimental design and testing of biological processes happened quite predictably at the level of short peptides (Hellberg et al., 1987). A range of 10â100 sequence variants were taken through at least two rounds of a design-build-test cycle using partial least squares and regression-based modeling, respectively, demonstrating the utility of active learning approaches in building predictive models for biological engineering problems (Mee et al., 1997; Norinder et al., 1997). Following the first wave of knowledge-based algorithm implementations in the 1990s, several reports demonstrated the feasibility of rapidly evolving proteins based on technological achievements in mutagenesis techniques, like DNA shuffling (Stemmer, 1994), as well as high-throughput screening methodologies, including phage display, automated sorting devices, and plate-based assays (Chaparro-Riggers et al., 2007; Crameri et al., 1996; Olsen et al., 2000; Zhang et al., 2002). Although many prior demonstrations of peptide to protein scale directed evolution exist, it was not until a seminal report by Fox et al. that machine learning concepts were extended to protein engineering in a way that allowed testing 1000s of âweakâ sequence-function hypotheses on a laboratory timescale, âŒ1 month per cycle (Fox et al., 2007). Briefly, several libraries of halohydrin dehalogenase, which plays a pivotal role in biosynthesis of the cholesterol-lowering drug Lipitor, were generated using a combination of rational and random mutagenesis strategies and quantitatively assessed on an individual basis. Importantly, the sequence-activity profiles for a broad range of activities were used to retrain a partial-least squares model correlating mutations with enzyme activity. Ultimately, the group discovered a sequence variant with 4,000-fold activity increase over wild-type. Continued advances in DNA synthesis now enable this same data-driven approach to be pursued in a completely rational manner, where at each stage the enzyme libraries can be synthesized according to whatever search algorithm is desired. More recently data-driven approaches have begun to surface at the scale of whole operons, inspiring the establishment of institutes like the Broad Foundry, where 1000s of pathway-scale constructs can be automatically built and arrayed for specific testing. Notably, constructing computational models with strong predictive power of pathway-level mutational effects can be hindered by the complexity of native regulatory networks as well as a lack of a priori knowledge about mutant-activity relationships. Alternatively, it is now possible to simply construct and test on the order of 10,000 alternative designs, and in this manner identify optimal designs in a âsynthesis aided designâ approach. Specifically, Smanski et al. refactored the Klebsiella oxytoca nitrogen fixation gene cluster without changing its function by (i) removing all non-coding DNA and regulatory elements, (ii) recoding each essential gene in the operon to remove any internal regulatory features including those yet to be discovered, and (iii) placing recoded genes into artificial operons whose expression levels are controlled by well characterized ribosome binding sites and spacer sequences (Smanski et al., 2014; Temme et al., 2012). Although the refactored cluster only retained 7% activity when expressed in E. coli with respect to the wild-type operon in its native host, this synthetic operon was able to serve as a foundation for applying active learning for iterative optimization. In fact, the most recent reports from this group have revealed the rapid assembly of tens of thousands of designs and optimal variants performing at close to 70% of wild-type activity. A series of reports suggest that we will soon see the âweakâ hypothesis approach demonstrated at the genome-scale. Wang and coworkers reported the multiplex automated genome engineering (MAGE) approach as a rapid method for constructing billions of combinatorial mutants spanning a targeted set of genes (Wang et al., 2009). The application of MAGE in many ways parallels the application of ProSAR described above with two key caveats. First, the size of combinatorial genome space requires that the initial search strategy was limited to a small number of pre-selected genes (27 in the case of Wang et al.) relative to the size of genome. Second, the ability to specifically test large numbers of individual MAGE mutants was not possible in the absence of whole-genome (or extremely long-read length) sequencing. The result was a very sparse mapping of genotype to phenotype relationships relative to what could be accomplished at either the protein or pathway levels as described above. In this manner, MAGE and several excellent follow up studies provided a set of impressive examples of how to rapidly and comprehensively construct combinatorial genome libraries, but several additional technologies were required to fully prove out weak-hypothesis driven genome engineering. The Trackable Multiplex Recombineering (TRMR) method (Warner et al., 2010) from our own group was developed to address the first caveat above. In TRMR, barcoded promoter mutants spanning the entire genome were constructed and then applied to map the effect of changes to an individual gene expression level onto a trait of interest. This approach could then be applied to find the smaller set of target genes required for combinatorial library generation via MAGE. We demonstrated precisely such an approach (Sandoval et al., 2012) in the engineering of cellulosic hydrolysate tolerance into E. coli. Although tolerance was improved, the study highlighted key technology limitations, such as the unpredictable efficiency of ssDNA recombineering (Reynolds and Gill, 2015), and emphasized the need to be able to track combinatorial mutants at much greater depth as described above. We recently reported an approach for addressing the latter of these issues by employing emulsion linking PCR to deeply characterize MAGE libraries (Zeitoun et al., 2015). In particular, we characterized population diversity in 4 out of 27 RBS sites across the E. coli genome that were combinatorially varied using MAGE, searching on the order of 105â106 genotypes, representing four orders of magnitude greater tracking-depth than previously possible. With respect to efficiency, the advent and broad applicability of CRISPR technologies could not have come at a better time (Doudna and Charpentier, 2014). CRISPR allows selection for specific genome modifications simply via the inclusion of a guide RNA targeting the CRISPR nuclease machinery to the wild-type sequence (Jiang et al., 2013, 2015). CRISPR has been employed to increase the efficiency of ssDNA recombineering to 95% or greater (Findlay et al., 2014; Fu et al., 2014; Pines et al., 2015). In combination, these technologies provide the remaining pieces for realization of highly efficient genome engineering and optimization via a âweakâ hypothesis driven strategy. What do these advances hold for the future of genome scale engineering? We are already seeing a rapid increase in the use of such technologies to demonstrate weak-hypothesis driven strain engineering (Cress et al., 2015; Li et al., 2015; Ronda et al., 2015; Salis et al., 2009) and the codification of this approach in the launching of several new bio-foundries (e.g., Zymergen, Synthetic Genomics, GingoBioworks, Copenhagen, Munich, Amyris, NYU, Edinburgh). These biofoundries operate at rates approximately 100Ă over the prior state of the art. Given the history of disruption of such machine-learning/weak-hypothesis approaches in parallel fields, we expect that the ship has sailed in terms of questioning this paradigm shift. Rather, the more relevant question is how we will most effectively take advantage of such a shift in the advancement of the field in general? Where are the most obvious application areas, both from a technology (protein or pathway or genome) and a product (antibodies, small molecules, etc.) perspective? How can we use the technology to develop the understanding of design rules required for construction of predictable models and what form will such models take (computational, biological, or both)? How do we restructure our workforce to address the increasing need for computational design and data analysis and reduced need for molecular cloning? Answers to these questions are not obvious, but the need to answer them is clear. We expect many answers will arise through large ongoing efforts from both the public and private sectors (see DARPA Living Foundries or recent financings of startups such as Twist, Gingko Bioworks, and Zymergen). Although centralized efforts are often effective, the community should continue to build upon decentralized efforts (e.g., iGEM, Foldit) that not only can provide a different perspective to such challenges but also help to disseminate technology and build a workforce. Doing so will require sustained support from funding agencies with missions tied to long-term impact as well as new ways of thinking about and judging the impact of innovations in this space. Ryan T. Gill, Andrea L. Halweg-Edwards Department of Chemical and Biological Engineering University of Colorado, Boulder Boulder, CO Aaron Clauset, Sam F. Way Department of Computer Science University of Colorado, Boulder Boulder, CO
On May 20, 1999, Nature published a brief report on an experiment performed by researchers at Cornell University that indicated that pollen from genetically modified (GM) Bt corn (Zea mays) could kill the larvae of monarch butterflies (Danaus plexippus). In laboratory tests, caterpillars fed milkweed (Asclepias curassavica) leaves dusted with pollen from a Bt corn hybrid showed retarded growth and increased mortality. âThese results,â the authors stated, âhave potentially profound implications for the conservation of monarch butterfliesâ (Losey et al., 1999). In a press release announcing the publication in Nature, the principal investigator on the Cornell study, John Losey, had expressed due caution: âPollen from Bt-corn could represent a serious risk to populations of monarchs and other butterflies, but we can't predict how serious the risk is until we have a lot more data. And we can't forget that Bt-corn and other transgenic crops have a huge potential for reducing pesticide use and increasing yields. This study is just the first step, we need to do more research and then objectively weigh the risks versus the benefits of this new technologyâ (Cornell News, 1999). Such caution was wasted on Greenpeace International. The day the findings of the Cornell study were published it already demanded that authorities in the United States, Argentina, Canada, and the European Union take immediate action and prohibit the growing of genetically engineered maize crops. The environmentalist nongovernmental organization (NGO) reiterated its earlier call for a ban on all releases of genetically modified organisms (GMOs). Less than a month later, in a media-oriented action, members of Greenpeace dressed up as butterflies confronted a meeting of European Union environment ministers held in Luxembourg, carrying banners demanding âGive butterflies a chance.â In Europe, their campaign apparently found resonance among the authorities: The European Commission decided to freeze the approval process for new Bt maize varieties. The Cornell study did not show that monarch butterfly populations in the wild were actually endangered by Bt corn. However, when Monsanto and Novartis, the companies that sold Bt corn at that time, correctly pointed out that the detrimental effects had so far only been shown in the laboratory, Greenpeace branded them as irresponsible. A spokesperson declared: âSuch reactions are the precise opposite to precaution and follow the same pattern of denial these companies have employed for decades, when health and environmental effects of their chemical pesticides were exposed. However, in the case of these GMOs we are talking about living toxins that can reproduce in nature and transmit their dangerous traits to wild species. We cannot consider GMOs harmless until harmful effects are fully proven (sic)â (Greenpeace, 1999a). (The last sentence is obviously aâFreudian?âslip of the tongue and should be read: âWe cannot consider GMOs harmless until the absence of harmful effects is fully proven.â) For Greenpeace, not just monarchs were supposed to be endangered. The NGO drew up a list of over 100 species of butterflies that it believed could be harmed by GM maize. It accused biotech companies and regulatory authorities of fully ignoring these risks (Greenpeace, 1999b). More recent field research performed in the American Midwest, however, seems to indicate that monarch butterfly populations are hardly affected, if at all, by the large-scale cultivation of Bt maize in this region (Ortman et al., 2001). The monarch butterfly case is only one among many occasions in which the so-called Precautionary Principle (PP) has been invoked to advocate preventative action to forestall possible harm even before the likelihood or the possible extent of the latter has been scientifically well established. This principle is highly contested. With many other environmentalist NGOs, Greenpeace champions its adoption as a central principle of international law against tenacious opposition from the United States, Canada, and Australia (Greenpeace, 2002). The principle is also at issue in recent World Trade Organization trade disputes between the United States and the European Union. But why does the PP play such a central role? The PP is an outgrowth of increased environmentalist awareness since the 1970s. The conviction took hold that humanity finds itself in a historically unprecedented situation in which our technological capacity and the potential scale of our actions far exceed our predictive knowledge. According to the German philosopher Hans Jonas, this discrepancy between the ability to foresee and the power to act itself assumes ethical importance and asks for humility and responsible restraint on our part. Jonas maintains that it is possible to extract from this situation of profound scientific uncertainty a rule or principle of decision making that is itself not uncertain at all, namely the rule âto give in matters of a certain magnitudeâthose with apocalyptic potentialâgreater weight to the prognosis of doom than to that of blissâ (Jonas, 1984). The supreme moral imperative in the new age, Jonas holds, is that humankind may not put its own existence and survival at stake in the wager of technological progress. If we want to find a philosophical basis for the PP, we must look for it in Jonas' book on the imperative of responsibility (although he himself did not use the expression PP). Environmentalists often hold that modern biotechnology has âapocalyptic potentialâ because it tampers with the basic processes of life. If we release GMOs into the environment, the ultimate consequences for the natural flora and fauna are extremely hard to predict but may well be irreversible. However, many environmentalists, just like Jonas, believe that we possess a decision rule or principle for dealing with fundamental scientific uncertainty that is itself not the least uncertain. That rule is the PP. Thus, in almost any debate, it seems that the PP can be brought in as a trump card to override all other considerations and arguments. But what exactly is the PP? Proponents of the PP assert that the principle is already âenshrinedâ in such international agreements as the Convention on Biological Diversity and the Cartagena Protocol on Biosafety, but existing definitions of it are at best partial and incomplete. In the context of dealing with environmental hazards, the Rio Declaration of 1992 presented the following formulation of what a precautionary approach entails: âWhere there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation.â A well-known definition of the PP was spelled out in a January 1998 meeting at Wingspread in Racine, Wisconsin. The Wingspread Statement summarized the principle thus: âWhen an activity raises threats of harm to human health or the environment, precautionary measures should be taken even if some cause and effect relationships are not fully established scientificallyâ (Raffensberger and Tickner, 1999). Definitions such as these beg many questions. Is there ever full scientific certainty? Do we need a minimal threshold of scientific certainty or plausibility before we may (or should) undertake preventative action? And do we really know how to prevent harm if we are so much ignorant about the underlying cause-effect relationships? The definitions that are currently on offer fail to spell out the precise conditions that have to be fulfilled before the PP may be invoked or the nature of the preventative action that has to be taken. The types of action suggested range from implementing a ban, imposing a moratorium while further research is conducted, allowing the potentially harmful activity to proceed while closely monitoring its effects, to just conducting more research. The PP does not have a very precise meaning as long as such crucial aspects are left largely unanswered. In practice, however, the PP is often given a more definite meaning by reducing it to an absurdity. Normally, no minimal threshold of plausibility is specified as a âtriggeringâ condition, so that even the slightest indication that a particular product or activity might possibly produce some harm to human health or the environment will suffice to invoke the principle. And just as often no other preventative action is contemplated than an outright ban on the incriminated product or activity. The intervention of Greenpeace in the monarch butterfly case seems to fit this pattern. Closely linked to various versions of the PP is the idea of reversing the onus of proof. Thus, the adherents of the Wingspread Statement declare that âthe applicant or proponent of an activity or process or chemical needs to demonstrate that the environment and public health will be safe. The proof must shift to the party or entity that will benefit from the activity and that is most likely to have the informationâ (Raffensberger and Tickner, 1999). Greenpeace also holds that effective implementation of the PP requires a shift in the burden of proof (Greenpeace, 2001). Shifting the burden of proof seems a fairly straightforward way to ensure, as Jonas demanded, that greater weight will be given to the âprognosis of doomâ than to the âprognosis of bliss.â Before looking into the proper assignment of the burden of proof, we must first examine more closely the underlying justification for the strong version of the PP. Why should the prospect of harmful effects of a new technology take precedence over the prospect of beneficial effects, quite apart from the inherent likelihood of each of these possibilities? The obvious answer seems to be that such a priority is defensible only when the harmful effects are of such magnitude that they carry catastrophic (or, as Jonas would say, âapocalypticâ) potential. The infinite costs of a possible catastrophic outcome necessarily outweigh even the slightest probability of its occurrence. This type of reasoning exhibits a remarkable resemblance to a well-known example of a âzero-infinity dilemma,â namely Pascal's famous âwager.â When it comes to wagering on the existence of God, the 17th century French philosopher argued incisively in his PenseÌes that it is better to be safe than sorry (Haller, 2000; Graham, 2002; Manson, 2002). Given an unknown but nonzero probability of God's existence and the infinity of the reward of an eternal life, the rational option would be to conduct one's earthly life as if God exists. Alas, Pascal's reasoning contains a fatal flaw. His argument is vulnerable to the âmany godsâ objection (Manson, 2002). Consider the possible existence of another deity than God, say Odin. If Odin is jealous, he will resent our worship of God, and we will have to pay an infinite price for our mistake. Never mind that Odin's existence may not seem likely or plausible to us. It is sufficient that we cannot exclude the possibility that he exists with absolute certainty. Therefore, the very same logic of Pascal's wager would lead us to adopt the opposite conclusion not to worship God. Pascal's argument, then, cannot be valid. If the wager argument is not valid, the strong version of the PP (which Manson dubs the âcatastrophe principleâ) cannot be valid either. Take the application of this principle to the problem of global warming. Environmentalists often argue that even if it is not conclusively established that the emission of carbon dioxide and other gases causes an enhanced greenhouse effect, the mere prospect of an ecological catastrophe due to such a scenario should lead us to drastically curb our emissions of greenhouse gases now. By the same logic, however, one could conjure up the possibility of a coming ice age. The mere prospect of this equally catastrophic scenario should then induce us to avert this outcome by stepping up the emission of greenhouse gases. Thus, the strong version of the PP would lead to contradictory recommendations (compare with Graham, 2002). In a similar way, it could be argued that this principle commits us to each of two contradictory policies: (a) We must not develop GM crops, and (b) We must develop GM crops. The first alternative is argued vehemently by many environmentalists who appeal to the PP. To support the second possibility, Gary Comstock conjures up a dramatic scenario in which people are forced to seize upon the remaining reserves of nature in a desperate effort to overcome food shortages resulting from global warming. He then argues, in the style of the environmentalists, that âlack of full scientific certainty that GM crops will prevent environmental degradation shall not be used as a reason for postponing this potentially cost-effective measureâ (Comstock, 2000). Therefore, the strong version of the PP is untenable. But what about the proposed shifting of the onus of proof toward those who advocate a new technology or activity? Reversing the burden of proof would amount to substituting the maxim âguilty until proven innocentâ for the age-old legal principle âinnocent until proven guilty.â Biotech enthusiasts and antiregulationists resent this departure from what they consider time-honored legal sanity (Miller and Conko, 2000). They are prone to counter the frequent invocation of the PP with an equally insistent demand of âsound science.â The same opposition is also at the center of the present World Trade Organization trade disputes between the United States and the European Union and their disagreement on the regulation of GM crops. One side claims the moral high ground, whereas the other side attempts to seize the scientific high ground. The situation is highly polarized because various economic and political interests are at stake (Fig. 1). Wheat (Triticum aestivum) fields in the Palouse region of the state of Washington in the United States. The polarized discussion about the PP and the adoption of GM crops has become a proxy for everything that Europeans and environmentalists in other countries don't like about modern agriculture. The rejection of agricultural biotechnology may perhaps be tolerated as a European indulgence but hardly makes sense on a global scale. The critics of the PP assert that the burden that environmentalists and regulators want to impose on the proponents of new technologies tends to be unbearable (Miller and Conko, 2000). In the name of absolute safety, the latter are asked nothing less than to demonstrate conclusively that the new technologies they advocate offer no possible harm. This is a formidable, perhaps even logically impossible, task. You cannot prove a negative (compare with Wildavsky, 1995). Moreover, a risk-free world is not a real option. Thus, a consistent application of the PP would in the final analysis stifle all innovation. A closer analysis of what is involved in applying the classical principle âinnocent until proven guilty,â however, reveals that the situation need not be as black and white as it seems at first sight. Take the paradigm case of criminal justice. There are two main ways in which a miscarriage of justice can come about. Either the suspect did not commit the crime, but the verdict found him guilty; or the suspect did commit the crime, but the verdict found him not guilty. In a civilized system of justice, the risks of the first type of error are minimized as far as possible. That is what is meant by the phrase âinnocent until proven guilty.â The system contains safeguards and precautions in the form of high standards of proof so as to ensure that a suspect will be condemned for a certain criminal offense only if it has been established âbeyond reasonable doubtâ that he in fact committed the alleged offense. Alas, there is a price to be paid for this cautious and civilized approach, namely the possibly large number of wrongdoers who have to be acquitted due to âlack of sufficient proof.â To a certain extent, the risks of the two types of error are inversely related. We may to the risk of an by demanding ever more standards of proof but only at the of increasing the risk of Therefore, we must that there is an involved in the of our system of criminal justice. We may to our standards as high as we but a must be the system will become by making it to sentence on the of there is a similar to be between the of a type or a type the of when it is in fact or to the when in fact it is By a we a particular this should on our of the and with of the two types of The analysis that the at issue is not just to burden of proof. as we for more or less standards of proof, an of In other the burden we want to put on the of one or the other party more or less on we our standards of proof more or less This may us to from the polarized opposition of PP versus In most companies to GM crops have to their to for health effects and environmental This can be more or less The of those who by âsound is a fully risk However, it is only possible to this in more and such as or are at then the expression âsound is because it the that necessarily into the of of and between type and type In other or more ecological effects are at the of the fully risk is of âsound will be to such less straightforward as or risks that can be However, as the proponents of the PP are in lack of of harm is not of lack of harm. If we are really about such hazards, we can put in effort to more about their plausibility or It would be to our with an appeal to âsound science.â A recent European on the release of GMOs into the environment that any that to or a transgenic should carry out a environmental risk into immediate and 2001). This new regulation of GM crops much further than some American also argue for a more approach et al., 2001). The new European a burden of proof on biotech companies to or not they are to take that burden on their will on the definition of a or for conducting environmental risk The to be is that the on these companies will become them at the of regulatory and for of environmental This will be enhanced by the fact that the of the has been by the PP and that regulatory authorities may give to the of GMOs only they have been that the release will be safe for human health and the The fairly of the environmental risk need not be in if of play for the regulation of GM crops can be More is also about the that have to be taken into in The outcome of the is for on or not in are taken as a or or not a strong to as a option is 2001). The and of a Bt maize hybrid or any other transgenic might be quite in than in the United States. Europeans are to because their countries lack of and other of regulatory at holds that the in on GM is not about safety, but is in fact a proxy for a on how should be 2001). GM crops have become a for all that Europeans don't like in modern agriculture. a for and a rejection of agricultural biotechnology perhaps may be tolerated as a European the prospect hardly makes sense on a global scale. this is what Greenpeace us as a the NGO us a serious answer to the of how to a growing world and natural the of modern biotechnology (compare with 1999). We can even press the environmentalist organization by the Thus, it that the polarized on the PP is just a proxy for a on the of world agriculture.